metricas
Revista Española de Medicina Nuclear e Imagen Molecular InmunoPET en oncología
Información de la revista
Vol. 41. Núm. 5.
Páginas 273-340 (Septiembre - Octubre 2022)
Cita
Cita
Compartir
Descargar PDF
Más opciones de artículo
Visitas
1792
Vol. 41. Núm. 5.
Páginas 273-340 (Septiembre - Octubre 2022)
Colaboración especial

InmunoPET en oncología

ImmunoPET in oncology
Visitas
1792
F. Mulero
Unidad de Imagen Molecular, Centro Nacional de Investigaciones Oncológicas, Madrid, España
Este artículo ha recibido
Información del artículo
Resumen
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Resumen

Con el auge de la inmunoterapia en oncología es fundamental tener una caracterización biológica de los tumores. Conocer que antígenos se expresan tanto en la superficie de la célula tumoral como en el microambiente del tumor para poder predecir la respuesta al tratamiento de los diferentes anticuerpos terapéuticos, se ha convertido en una necesidad. La inmunoPET es una herramienta de diagnóstico por imagen, no invasiva, que aúna la elevada especificidad de los anticuerpos frente a los antígenos con la elevada sensibilidad, resolución y capacidad de cuantificación de la imagen PET. Con la inmunoPET obtenemos una biopsia virtual del tumor con un amplísimo presente y futuro en investigación preclínica-clínica, siendo ya una realidad en la predicción y monitorización de la respuesta a los tratamientos con anticuerpos monoclonales, permitiendo una selección de pacientes y terapias alcanzando una autentica medicina personalizada contribuyendo a mejorar las decisiones clínicas.

Palabras clave:
InmunoPET
Oncología
Inmunoterapia
Abstract

Due to increase of immunotherapy in oncology, it is essential to have a biological characterization of tumors. Knowing which antigens are expressed both on the surface of the tumor cell and at tumor microenvironment in order to predict the tretment response different therapeutic antibodies, has become a need. ImmunoPET is a non-invasive diagnostic imaging tool that combines the high specificity of antibodies against antigens with the high sensitivity, resolution and quantification capacity of PET imaging. With ImmunoPET we obtain a virtual biopsy of tumors, it has a big present and future in preclinical-clinical research, being already a reality in predicting and monitoring the response to treatments with monoclonal antibodies, allowing a selection of patients and therapies reaching a personalized medicine contributing to improve clinical decisions.

Keywords:
ImmunoPET
Oncology
Immunotherapy

Artículo

Opciones para acceder a los textos completos de la publicación Revista Española de Medicina Nuclear e Imagen Molecular
Suscriptor
Suscriptor de la revista

Si ya tiene sus datos de acceso, clique aquí.

Si olvidó su clave de acceso puede recuperarla clicando aquí y seleccionando la opción "He olvidado mi contraseña".
Comprar
Comprar acceso al artículo

Comprando el artículo el PDF del mismo podrá ser descargado

Comprar ahora
Contactar
Teléfono para suscripciones e incidencias
De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h
Llamadas desde España
932 415 960
Llamadas desde fuera de España
+34 932 415 960
E-mail
Bibliografía
[1]
W. Wei, Z.T. Rosenkrans, J. Liu, G. Huang, Q.Y. Luo, W. Cai.
ImmunoPET: Concept, Design, and Applications.
Chem Rev., 120 (2020), pp. 3787-3851
[2]
Trastuzumab and Breast Cancer.
N Engl J Med., 345 (2001), pp. 995-998
[3]
J. Dewulf, K. Adhikari, C. Vangestel, T.V. Wyngaert, F. Elvas.
Development of Antibody Immuno-PET/SPECT Radiopharmaceuticals for Imaging of Oncological Disorders—An Update.
Cancers., 12 (2020), pp. 1868
[4]
C. Gerke, I. Zabala Gutierrez, D. Méndez-González, M.C. Iglesias de la Cruz, F. Mulero, D. Jaque, et al.
Clickable Albumin Nanoparticles for Pretargeted Drug Delivery toward PD-L1 Overexpressing Tumors in Combination Immunotherapy.
Bioconjug Chem., 33 (2022), pp. 821-828
[5]
G.W. Philpott, S.W. Schwarz, C.J. Anderson, F. Dehdashti, J.M. Connett, K.R. Zinn, et al.
RadioimmunoPET: detection of colorectal carcinoma with positron-emitting copper-64-labeled monoclonal antibody.
J Nucl Med., 36 (1995), pp. 1818-1824
[6]
D.M. Goldenberg, H.A. Nabi.
Breast cancer imaging with radiolabeled antibodies.
Semin Nucl Med., 29 (1999), pp. 41-48
[7]
R. Laforest, S.E. Lapi, R. Oyama, R. Bose, A. Tabchy, B.V. Marquez-Nostra, et al.
[89Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer.
Mol Imaging Biol., 18 (2016), pp. 952-959
[8]
E.C.F. Dijkers, J.G.W. Kosterink, A.P. Rademaker, L.R. Perk, G.A.M.S. van Dongen, J. Bart, et al.
Development and Characterization of Clinical-Grade 89/Zr-Trastuzumab for HER2/neu/ImmunoPET Imaging.
J Nucl Med., 50 (2009), pp. 974-981
[9]
S. Reddy, M.K. Robinson.
Immuno-Positron Emission Tomography in Cancer Models.
Semin Nucl Med., 40 (2010), pp. 182-189
[10]
A.G. de Lucas, A.J. Schuhmacher, M. Oteo, E. Romero, J.A. Cámara, A. de Martino, et al.
Targeting MT1-MMP as an ImmunoPET-Based Strategy for Imaging Gliomas.
PLoS One., 11 (2016), pp. e0158634
[11]
A.O. Alamoudi.
Radiomics aptamers and nanobodies: New insights in cancer diagnostics and imaging.
Hum Antibodies., 29 (2021), pp. 1-15
[12]
C. Van Elssen, M. Rashidian, V. Vrbanac, K.W. Wucherpfennig, Z.E. Habre, J. Sticht, et al.
Noninvasive Imaging of Human Immune Responses in a Human Xenograft Model of Graft-Versus-Host Disease.
J Nucl Med., 58 (2017), pp. 1003-1008
[13]
S.M. Knowles, A.M. Wu.
Advances in Immuno–Positron Emission Tomography: Antibodies for Molecular Imaging in Oncology.
J Clin Oncol., 30 (2012), pp. 3884-3892
[14]
H. Luo, H. Hong, S.P. Yang, W. Cai.
Design and Applications of Bispecific Heterodimers: Molecular Imaging and beyond.
Mol Pharm., 11 (2014), pp. 1750-1761
[15]
T. Kromann-Hansen, E. Oldenburg, K.W. Yung, G.H. Ghassabeh, S. Muyldermans, P.J. Declerck, et al.
A Camelid-derived Antibody Fragment Targeting the Active Site of a Serine Protease Balances between Inhibitor and Substrate Behavior.
J Biol Chem., 291 (2016), pp. 15156-15168
[16]
C. Ackaert, N. Smiejkowska, C. Xavier, Y.G.J. Sterckx, S. Denies, B. Stijlemans, et al.
Immunogenicity Risk Profile of Nanobodies.
Front Immunol., 12 (2021), pp. 632687
[17]
B. Altunay, A. Morgenroth, M. Beheshti, A. Vogg, N.C.L. Wong, H.H. Ting, et al.
HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging.
Eur J Nucl Med Mol Imaging., 48 (2021), pp. 1371-1389
[18]
G. Bala, A. Blykers, C. Xavier, B. Descamps, A. Broisat, C. Ghezzi, et al.
Targeting of vascular cell adhesion molecule-1 by 18F-labelled nanobodies for PET/CT imaging of inflamed atherosclerotic plaques.
Eur Heart J Cardiovasc Imaging., 17 (2016), pp. 1001-1008
[19]
L. Berland, L. Kim, O. Abousaway, A. Mines, S. Mishra, L. Clark, et al.
Nanobodies for Medical Imaging: About Ready for Prime Time?.
Biomolecules., 11 (2021), pp. 637
[20]
G. Lv, X. Sun, L. Qiu, Y. Sun, K. Li, Q. Liu, et al.
PET Imaging of Tumor PD-L1 Expression with a Highly Specific Nonblocking Single-Domain Antibody.
J Nucl Med., 61 (2020), pp. 117-122
[21]
A.M. Wu, T. Olafsen.
Antibodies for molecular imaging of cancer.
[22]
M. Brennan, P.F. Davison, H. Paulus.
Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments.
[23]
H. Byrne, P.J. Conroy, J.C. Whisstock, R.J. O’Kennedy.
A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications.
Trends Biotechnol., 31 (2013), pp. 621
[24]
Y. Zhou, J. Li, X. Xu, M. Zhao, B. Zhang, S. Deng, et al.
64Cu-based Radiopharmaceuticals in Molecular Imaging.
Technol Cancer Res Treat., 18 (2019),
[25]
Y. Dun, G. Huang, J. Liu, W. Wei.
ImmunoPET imaging of hematological malignancies: From preclinical promise to clinical reality.
Drug Discov Today., 27 (2022), pp. 1196-1203
[26]
R. Fu, L. Carroll, G. Yahioglu, E.O. Aboagye, P.W. Miller.
Antibody Fragment and Affibody ImmunoPET Imaging Agents: Radiolabelling Strategies and Applications.
ChemMedChem., 13 (2018), pp. 2466-2478
[27]
B. Traenkle, P.D. Kaiser, S. Pezzana, J. Richardson, M. Gramlich, T.R. Wagner, et al.
Single-Domain Antibodies for Targeting Detection, and In Vivo Imaging of Human CD4(+) Cells.
Front Immunol., 12 (2021), pp. 799910
[28]
C.W. Menke-van der Houven van Oordt, E.C. Gootjes, M.C. Huisman, D.J. Vugts, C. Roth, A.M. Luik, et al.
89Zr-cetuximab PET imaging in patients with advanced colorectal cancer.
Oncotarget., 6 (2015), pp. 30384-30393
[29]
A.J.G. Even, O. Hamming-Vrieze, W. van Elmpt, V.J.L. Winnepenninckx, J. Heukelom, M.E.T. Tesselaar, et al.
Quantitative assessment of Zirconium-89 labeled cetuximab using PET/CT imaging in patients with advanced head and neck cancer: a theragnostic approach.
Oncotarget., 8 (2017), pp. 3870-3880
[30]
K. Leung.
(64)Cu-1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid-epidermal growth factor receptor-binding fibronectin domain E13.4.3’.
Molecular Imaging and Contrast Agent Database (MICAD) [internet], National Center for Biotechnology Information (US), (2004),
[31]
K. Leung.
IRDye 800CW-Anti-epidermal growth factor receptor nanobody 7D12.
Molecular Imaging and Contrast Agent Database (MICAD) [internet], National Center for Biotechnology Information (US), (2004),
[32]
K. Leung.
(68)Ga-Desferrioxamine p-isothiocyanatobenzyl-anti-EGFR nanobody 7D12.
Molecular Imaging and Contrast Agent Database (MICAD) [internet], National Center for Biotechnology Information (US), (2004),
[33]
K. Leung.
(89)Zr-Desferrioxamine p-isothiocyanatobenzyl-anti-EGFR nanobody 7D12.
Molecular Imaging and Contrast Agent Database (MICAD) [internet], National Center for Biotechnology Information (US), (2004),
[34]
R. Chekol, V.R. Solomon, E. Alizadeh, W. Bernhard, D. Fisher, W. Hill, et al.
(89)Zr-nimotuzumab for immunoPET imaging of epidermal growth factor receptor I.
Oncotarget., 9 (2018), pp. 17117-17132
[35]
G.A. Ulaner, D.M. Hyman, S.K. Lyashchenko, J.S. Lewis, J.A. Carrasquillo.
89Zr-Trastuzumab PET/CT for Detection of Human Epidermal Growth Factor Receptor 2-Positive Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer.
Clin Nucl Med., 42 (2017), pp. 912-917
[36]
K. Tamura, H. Kurihara, K. Yonemori, H. Tsuda, J. Suzuki, Y. Kono, et al.
64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer.
J Nucl Med., 54 (2013), pp. 1869-1875
[37]
G.A. Ulaner, S.K. Lyashchenko, C. Riedl, S. Ruan, P.B. Zanzonico, D. Lake, et al.
First-in-Human Human Epidermal Growth Factor Receptor 2–Targeted Imaging Using 89Zr-Pertuzumab PET/CT: Dosimetry and Clinical Application in Patients with Breast Cancer.
J Nucl Med., 59 (2018), pp. 900-906
[38]
V. Beylergil, P.G. Morris, P.M. Smith-Jones, S. Modi, D. Solit, C.A. Hudis, et al.
Pilot study of 68Ga-DOTA-F(ab’)2-trastuzumab in patients with breast cancer.
Nucl Med Commun., 34 (2013), pp. 1157-1165
[39]
Z. Zhou, N. Devoogdt, M.R. Zalutsky, G. Vaidyanathan.
An Efficient Method for Labeling Single Domain Antibody Fragments with (18)F Using Tetrazine- Trans-Cyclooctene Ligation and a Renal Brush Border Enzyme-Cleavable Linker.
Bioconjug Chem., 29 (2018), pp. 4090-4103
[40]
Z. Zhou, G. Vaidyanathan, D. McDougald, C.M. Kang, I. Balyasnikova, N. Devoogdt, et al.
Fluorine-18 Labeling of the HER2-Targeting Single-Domain Antibody 2Rs15d Using a Residualizing Label and Preclinical Evaluation.
Mol Imaging Biol., 19 (2017), pp. 867-877
[41]
W. Wei, Z.T. Rosenkrans, J. Liu, G. Huang, Q.Y. Luo, W. Cai.
ImmunoPET: Concept, Design, and Applications.
Chem Rev., 120 (2020), pp. 3787-3851
[42]
C.G. Willett, Y. Boucher, E. di Tomaso, D.G. Duda, L.L. Munn, R.T. Tong, et al.
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.
Nat Med., 10 (2004), pp. 145-147
[43]
K. Muylle, P. Flamen, D.J. Vugts, T. Guiot, G. Ghanem, N. Meuleman, et al.
Tumour targeting and radiation dose of radioimmunotherapy with 90Y-rituximab in CD20+B-cell lymphoma as predicted by 89Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab.
Eur J Nucl Med Mol Imaging., 42 (2015), pp. 1304-1314
[44]
H. Sun, C.G. England, R. Hernandez, S.A. Graves, R.L. Majewski, A. Kamkaew, et al.
ImmunoPET for assessing the differential uptake of a CD146-specific monoclonal antibody in lung cancer.
Eur J Nucl Med Mol Imaging., 43 (2016), pp. 2169-2179
[45]
Y. Zhang, H. Hong, H. Orbay, H.F. Valdovinos, T.R. Nayak, C.P. Theuer, et al.
PET imaging of CD105/endoglin expression with a 61/64Cu-labeled Fab antibody fragment.
Eur J Nucl Med Mol Imaging., 40 (2013), pp. 759-767
[46]
J.L. Houghton, B.M. Zeglis, D. Abdel-Atti, R. Sawada, W.W. Scholz, J.S. Lewis.
Pretargeted Immuno-PET of Pancreatic Cancer: Overcoming Circulating Antigen and Internalized Antibody to Reduce Radiation Doses.
J Nucl Med., 57 (2016), pp. 453
[47]
A. Crawford, L. Haber, M.P. Kelly, K. Vazzana, L. Canova, P. Ram, et al.
A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer.
Sci Transl Med., 11 (2019), pp. eaau7534
[48]
T. Langbein, G. Chaussé, R.P. Baum.
Salivary Gland Toxicity of PSMA Radioligand Therapy: Relevance and Preventive Strategies.
J Nucl Med., 59 (2018), pp. 1172
[49]
G. Vaidyanathan, D. McDougald, J. Choi, E. Koumarianou, D. Weitzel, T. Osada, et al.
Preclinical Evaluation of 18F-Labeled Anti-HER2 Nanobody Conjugates for Imaging HER2 Receptor Expression by Immuno-PET.
J Nucl Med., 57 (2016), pp. 967-973
[50]
W. Wei, D. Jiang, E.B. Ehlerding, Q. Luo, W. Cai.
Noninvasive PET Imaging of T cells.
Trends Cancer., 4 (2018), pp. 359-373
[51]
N. Pandit-Taskar, M.A. Postow, M.D. Hellmann, J.J. Harding, C.A. Barker, J.A. O’Donoghue, et al.
First-in-Humans Imaging with (89)Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics Biodistribution, and Lesion Targeting.
J Nucl Med., 61 (2020), pp. 512-519
[52]
J.W. Seo, R. Tavaré, L.M. Mahakian, M.T. Silvestrini, S. Tam, E.S. Ingham, et al.
CD8(+) T-Cell Density Imaging with (64)Cu-Labeled Cys-Diabody Informs Immunotherapy Protocols.
Clin Cancer Res., 24 (2018), pp. 4976-4987
[53]
E.B. Ehlerding, C.G. England, R.L. Majewski, H.F. Valdovinos, D. Jiang, G. Liu, et al.
ImmunoPET Imaging of CTLA-4 Expression in Mouse Models of Non-small Cell Lung Cancer.
Mol Pharm., 14 (2017), pp. 1782-1789
[54]
A.N. Niemeijer, D. Leung, M.C. Huisman, I. Bahce, O.S. Hoekstra, G. van Dongen, et al.
Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer.
Nat Commun., 9 (2018), pp. 4664
[55]
M. Xu, Y. Han, G. Liu, Y. Xu, D. Duan, H. Liu, et al.
Preclinical Study of a Fully Human Anti-PD-L1 Antibody as a Theranostic Agent for Cancer Immunotherapy.
Mol Pharm., 15 (2018), pp. 4426-4433
[56]
I.S. Alam, A.T. Mayer, I. Sagiv-Barfi, K. Wang, O. Vermesh, D.K. Czerwinski, et al.
Imaging activated T cells predicts response to cancer vaccines.
J Clin Invest., 128 (2018), pp. 2569-2580
[57]
M.C.H. Hekman, M. Rijpkema, E.H. Aarntzen, S.F. Mulder, J.F. Langenhuijsen, E. Oosterwijk, et al.
Positron Emission Tomography/Computed Tomography with (89)Zr-girentuximab Can Aid in Diagnostic Dilemmas of Clear Cell Renal Cell Carcinoma Suspicion.
Eur Urol., 74 (2018), pp. 257-260
[58]
M. Morcillo, Á. García de Lucas, M. Oteo, E. Romero, N. Magro, M. Ibáñez, et al.
MT1-MMP as a PET Imaging Biomarker for Pancreas Cancer Management.
Contrast Media Mol Imaging., 2018 (2018), pp. 8382148
asdasdasd
Opciones de artículo
Herramientas